September 9, 2020 Comments Off on Vicapsys Life Sciences, Inc. (VICP) Investment Losses Blog, Current Investigations

Vicapsys Life Sciences, Inc. (VICP) Investment Losses

Vicapsys Life Sciences, Inc. (VICP) Investment Losses, featured by top securities fraud attorneys, The White Law Group

Concerned about your investment in Vicapsys Life Sciences, Inc. (VICP)? 

Are you concerned about your investment losses in Vicapsys Life Sciences, Inc. (VICP)? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Vicapsys Life Sciences, Inc., based in Cumming, GA,  is a development stage biotechnology company, which advances proprietary localized immune modulator. Its initial pipeline products include type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation, according to MarketWatch.

The company filed a form D to raise capital from investors in 2018, according to filings with the SEC. The total offering amount was purportedly $6,000,000, with an estimated 10% paid in sales commissions and fees.

According to the most recent financial statements filed in May 2020,  the Company experienced a net loss of $364,459 for the three months ended March 31, 2020, had a working capital deficit of $487,189 and an accumulated deficit of $13,491,369 as of March 31, 2020. The company noted that “these factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business.”

Filing a Complaint against your Brokerage Firm

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.

The problem with pharmaceutical and biotech investments such as Vicapsys Life Sciences, Inc. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Vicapsys Life Sciences Inc., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

Comments are closed.